Oral acute and subchronic toxicity of D-004, a lipid extract from Roystonea regia fruits, in rats

Drugs under Experimental and Clinical Research

Volumn 31, Issue 3, 2005, Pages 101-108

  Gamez R ^a   Mas, R ^a   Noa, M ^a   Menendez R ^a   Garcia H ^a   Rodriguez Y ^a,a   Felipe, E ^a   Goicochea, E ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

D 004; FATTY ACID ESTER; LIPID; PLANT EXTRACT; ROYSTONEA REGIA EXTRACT; TESTOSTERONE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG ISOLATION; FEMALE; FRUIT; HISTOPATHOLOGY; MALE; NONHUMAN; ORGAN WEIGHT; PLANT; PROSTATE HYPERTROPHY; RAT; ROYSTONEA REGIA; TOXICITY TESTING; WEIGHT GAIN;

ACUTE TOXICITY TESTS; ADMINISTRATION, ORAL; ANIMALS; ARECACEAE; FEMALE; FRUIT; LIPIDS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS, CHRONIC;

EID: 21744454018     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Clinton J.J. Benign prostatic hyperplasia (BPH)-diagnosis and treatment. JAMA, 271, 1152, 1994.
2. McCarthy M. BPH guidelines. Lancet, 343, 473, 1994.
3. Oesterling J.E. Benign prostatic hyperplasia: Medical and minimal invasive treatment options. NEJM, 332, 99, 1995.
4. Barry M.J., Roehrborn C.G. Benign prostatic hyperplasia. BMJ, 323, 1042, 2001.
5. Carson C., Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(Suppl. 1), 2, 2003.
6. Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A, 41, 412, 2002.
7. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology, 48, 398, 1996.
8. Andro M.C., Riffaud J.P. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr Ther. Res., 56, 1, 1005, 1995.
9. Rhodes L., Primka R.L., Berman C., et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate, 22, 43, 1993.
10. Small J.K., Bombardelli E., Morazzoni P. Serenoa repens (Bartram). Fitoterapia, 99, 113, 1997.
11. Plosker G.L., Brodgen R.N. Serenoa repens (Permixon): A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs & Aging, 9, 379, 1996
12. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA, 280, 1604, 1998.
13. Gordon A.E., Shaughnessy A.F. Saw palmetto for prostate disorders. Am. Fam. Physician, 67, 1281, 2003
14. Goepel M., Hecker U., Krege S., et al. Saw palmetto extracts potently and non-competitively inhibit human alpha 1 adrenoceptors in vitro. Prostate, 38, 208, 1999.
15. Marks E. Effects of Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol., 163, 1451, 2000.
16. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate, 29, 231, 1996.
17. Paubert-Braquet M., Mencia Huerta J.M. Cousse H., Braquet P. Effect of the lipidic lipidosterolic extract of serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostagland. Leukot. Essen. Fatty Acids, 57, 299, 1997
18. Paubert-Braquet M., Richardson F.O., Servent-Saez N., et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol. Res., 34, 171, 1996.
19. Chaudry A.A., Wahle K.W., McClinton S., Moffat L.E. Arachidonic acid metabolism in benign and malignant prostate tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int. J. Cancer, 57, 176, 1994.
20. Carbin B.E., Larsson B., Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br. J. Urol., 66, 639, 1990.
21. "Scott Zona Notes on Roystonea in Cuba," Principes, 35, 225, 1991.
22. Laguna A., Rodríguez E., Carvajal D., et al., inventors. Laboratorios Dalmer S.A. asignee. Pharmaceutical composition and procedure for the prevention and treatment of prostate hyperplasia and prostatitis obtained from the fruits of Roystonea regia (Cuban royal palm). Cuban patent number WO 2004/082696 A1, Sept. 30, 2004.
23. Arruzazabala M.L., Carbajal D., Mas R., Molina V., Rodriguez E., Gonzalez V. Preventive effects of D-004, a lipid extract from Cuban royal palm (Rostoynea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exptl. Clin. Res., 30, 227, 2004.
24. Landsdown A.B. Animal husbandry in experimental toxicology. In: Gad S.C. Shengelis C.R (Eds.). "Experimental, The Basic Issues." Second edition. Marcel Dekker Inc., New York, 1993, pp. 101-112.
25. Wolford S.T., Schorer R.A., Gohs F.X., et al. Reference database for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Health, 18, 161, 1986.
26. Schlede E., Mischke U., Diener W., Kayser D. The international validation study of the acute toxic class method (oral). Arch. Toxicol., 69, 659, 1995.
27. Dorato M.A., Jo Voracnik M. The toxicology assessment of pharmaceutical and biotechnology products. In: Hayes W. (Ed.), "Principles and Methods of Toxicology." Raven Press Ltd., New York, 1994, pp. 189-219.
28. Voss G., Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animals blood determinated simultaneosly by a modified acetylthiocholine-DTNB procedure. Toxicol. Appl. Pharmacol., 16, 764, 1970.
29. Long G., Symanowski T., Roback K. Precision in data acquisition and reporting of organ weights in rats and mice. Toxicol. Pathol., 26, 316, 1998.
30. Hall R. Clinical pathology of laboratory animals. In: "Product Safety Evaluation Handbook." Gad S.C. (Ed.). Marcel Dekker Inc. New York, 1999, pp. 765-811
31. Piccirillo V.J. Repeated-dose toxicity studies. In: Gad S.C. (Ed.). "Product Safety Evaluation Handbook." Marcel Dekker Inc., New York, 1999, pp. 201-222.
32. Gad S.C., Weil C. Statistics for toxicologists. In: Hayes W. (Ed.). "Principles and Methods of Toxicology." Second edition. Raven press Ltd., New York, 1989, pp. 435-483.
33. Alemán C.L., Más R., Rodeiro I., et al. Reference database of the main physiological parameters in Sprague Dawley rats from 6 to 32 months. Lab. Anim., 32, 457, 1998.